Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport

Molecular Cancer Therapeutics

Volumn 13, Issue 12, 2014, Pages 2805-2816

  Bola, Becky M ^a,b   Chadwick, Amy L ^a,c   Michopoulos, Filippos ^d   Blount, Kathryn G ^a   Telfer, Brian A ^a   Williams, Kaye J ^a   Smith, Paul D ^d   Critchlow, Susan E ^d   Stratford, Ian J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; AZD 3965; GLUCOSE; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLYCOLYTIC ENZYME; LACTIC ACID; MONOCARBOXYLATE TRANSPORTER 1; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; AZD3965; COTRANSPORTER; LACTIC ACID DERIVATIVE; MONOCARBOXYLATE TRANSPORT PROTEIN 1; MONOCARBOXYLATE TRANSPORTER; PYRIMIDINONE DERIVATIVE; THIOPHENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME KINETICS; FEMALE; GLUCOSE TRANSPORT; IN VIVO STUDY; METABOLOMICS; MOUSE; NONHUMAN; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; SMALL CELL LUNG CANCER; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; CLUSTER ANALYSIS; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GLYCOLYSIS; HUMAN; METABOLISM; MORTALITY; NEOPLASMS; OXIDATIVE STRESS; PATHOLOGY; RADIATION DOSE; RADIATION RESPONSE; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CLUSTER ANALYSIS; DISEASE MODELS, ANIMAL; FEMALE; GLYCOLYSIS; HUMANS; LACTATES; METABOLOMICS; MONOCARBOXYLIC ACID TRANSPORTERS; NEOPLASMS; OXIDATIVE STRESS; PYRIMIDINONES; RADIATION TOLERANCE; SYMPORTERS; THIOPHENES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84918565034     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-1091     Document Type: Article

References (49)

1. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OCA. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638-48.
2. Karar J, Maity A. Modulating the tumor microenvironment to increase radiation responsiveness. Cancer Biol Ther 2009;8:1994-2001.
3. Koch CJ, Kruuv J, Frey HE. Variation in radiation response of mammalian cells as a function of oxygen tension. Radiat Res 1973;53:33-42.
4. Yasuda H. Solid tumor physiology and hypoxia-induced chemo/radioresistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer. Nitric Oxide 2008;19:205-16.
5. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009;8:3984-4001.
6. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
7. Hirschhaeuser F, Sattler UG, Mueller-Klieser W. Lactate: a metabolic key player in cancer. Cancer Res 2011;71:6921-5.
8. Fulham MJ, Bizzi A, Dietz MJ, Shih HH, Raman R, Sobering GS, et al. Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology 1992;185:675-86.
9. Hossmann KA, Mies G, Paschen W, Szabo L, Dolan E, Wechsler W. Regional metabolism of experimental brain tumors. Acta Neuropathol 1986;69:139-47.
10. Kennedy KM, Dewhirst MW. Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol 2010;6:127-48.
11. Paschen W, Djuricic B, Mies G, Schmidt-Kastner R, Linn F. Lactate and pH in the brain: association and dissociation in different pathophysiological states. J Neurochem 1987;48:154-9.
12. Yokota H, Guo J, Matoba M, Higashi K, Tonami H, Nagao Y. Lactate, choline, and creatine levels measured by vitro 1H-MRS as prognostic parameters in patients with non-small cell lung cancer. J Magn Reson Imaging 2007;25:992-9.
13. Halestrap AP, Price NT. The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem J 1999;343:281-99.
14. Ovens MJ, Davies AJ, Wilson MC, Murray CM, Halestrap AP. AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10. Biochem J 2010;425:523-30.
15. Halestrap AP, Meredith D. The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Arch 2004;447:619-28.
16. Juel C, Halestrap AP. Lactate transport in skeletal muscle - role and regulation of the monocarboxylate transporter. J Physiol 1999;517:633-42.
17. Ullah MS, Davies AJ, Halestrap AP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem 2006;281:9030-7.
18. Bonen A. The expression of lactate transporters (MCT1 and MCT4) in heart and muscle. Eur J Appl Physiol 2001;86:6-11.
19. Dubouchaud H, Butterfield GE, Wolfel EE, Bergman BC, Brooks GA. Endurance training, expression, and physiology of LDH, MCT1, and MCT4 in human skeletal muscle. Am J Physiol Endocrinol Metab 2000;278:E571-9.
20. Manning Fox JE, Meredith D, Halestrap AP. Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle. J Physiol 2000;529:285-93.
21. Bergersen LH. Is lactate food for neurons? Comparison of monocarboxylate transporter subtypes in brain and muscle. Neuroscience 2007;145:11-9.
22. Brooks GA. Lactate shuttles in nature. Biochem Soc Trans 2002;30:258-64.
23. Pellerin L. Lactate as a pivotal element in neuron-glia metabolic cooperation. Neurochem Int 2003;43:331-8.
24. Sonveaux P, Végran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, et al., Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 2008;118:3930-42.
25. Martinez-Outschoorn UE, Balliet RM, Lin Z, Whitaker-Menezes D, Howell A, Sotgia F, et al. Hereditary ovarian cancer and two-compartment tumor metabolism: epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NFkappaB activation in the tumor stroma. Cell Cycle 2012;11:4152-66.
26. Fiaschi T, Chiarugi P. Oxidative stress, tumor microenvironment, and metabolic reprogramming: a diabolic liaison. Int J Cell Biol 2012;2012:762825.
27. Pinheiro C, Albergaria A, Paredes J, Sousa B, Dufloth R, Vieira D, et al. Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma. Histopathology 2010;56:860-7.
28. Chen H, Wang L, Beretov J, Hao J, Xiao W, Li Y. Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression. Clin Exp Metastasis 2010;27:557-69.
29. Pinheiro C, Longatto-Filho A, Simoes K, Jacob CE, Bresciani CJ, Zilberstein B, et al. The prognostic value of CD147/EMMPRIN is associated with monocarboxylate transporter 1 co-expression in gastric cancer. Eur J Cancer 2009;45:2418-24.
30. Pinheiro C, Longatto-Filho A, Scapulatempo C, Ferreira L, Martins S, Pellerin L, et al. Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch 2008;452:139-46.
31. Kim HS, Masko EM, Poulton SL, Kennedy KM, Pizzo SV, Dewhirst MW, et al. Carbohydrate restriction and lactate transporter inhibition in a mouse xenograft model of human prostate cancer. BJU Int 2012;110:1062-9.
32. Miranda-Gonc¸alves V, Honavar M, Pinheiro C, Martinho O, Pires MM, Pinheiro C, et al. Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro Oncol 2013;15:172-88.
33. Colen CB, Shen Y, Ghoddoussi F, Yu P, Francis TB, Koch BJ, et al. Metabolic targeting of lactate efflux by malignant glioma inhibits invasiveness and induces necrosis: an in vivo study. Neoplasia 2011;13:620-32.
34. Halestrap AP. e-letter: inhibiting lactate oxidation in tumor cells. J Clin Invest 2008;118 3930-42.
35. Busk M, Walenta S, Mueller-Klieser W, Steiniche T, Jakobsen S, Horsman MR, et al. Inhibition of tumor lactate oxidation: consequences for the tumor microenvironment. Radiother Oncol 2011;99:404-11.
36. Bueno V, Binet I, Steger U, Bundick R, Ferguson D, Murray C, et al. The specific monocarboxylate transporter (MCT1) inhibitor, AR-C117977, a novel immunosuppressant, prolongs allograft survival in the mouse. Transplantation 2007;84:1204-7.
37. Ekberg H, Qi Z, Pahlman C, Veress B, Bundick RV, Craggs RI, et al. The specific monocarboxylate transporter-1 (MCT-1) inhibitor, ARC117977, induces donor-speci fic suppression, reducing acute and chronic allograft rejection in the rat. Transplantation 2007;84:1191-9.
38. Le Floch R, Chiche J, Marchiq I, Naiken T, Ilic K, Murray CM, et al. CD147 subunit of lactate/H+symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc Natl Acad Sci U S A 2011;108:16663-8.
39. Critchlow SE, Hopcroft L, Mooney L, Curtis N, Whalley N, Zhong H, et al. Pre-clinical targeting of the metabolic phenotype of lymphoma by AZD3965, a selective inhibitor of monocarboxylate transporter 1 (MCT1) [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL: AACR; 2012. Abstract nr 3224.
40. http://science.cancerresearchuk.org/.
41. Swainston N, Golebiewski M, Messiha HL, Malys N, Kania R, Kengne S, et al. Enzyme kinetics informatics: from instrument to browser. FEBS J 2010;277:3769-79.
42. Williams KJ, Telfer BA, Shannon AM, Babur M, Stratford IJ, Wedge SR. Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit. Mol Cancer Ther 2007;6:599-606.
43. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010;102:1555-77.
44. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006;126:107-20.
45. Gottlieb E, Vousden KH. p53 regulation of metabolic pathways. Cold Spring Harb Perspect Biol 2010;2:a001040.
46. Semenza GL. Regulation of metabolism by hypoxia-inducible factor 1. Cold Spring Harb Symp Quant Biol 2011;76:347-53.
47. Whitaker-Menezes D, Martinez-Outschoorn UE, Lin Z, Ertel A, Flomenberg N, Witkiewicz AK, et al. Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fi broblasts. Cell Cycle 2011;10:1772-83.
48. Halestrap AP. The monocarboxylate transporter family-structure and functional characterization. IUBMB Life 2012;64:1-9.
49. Kennedy KM, Scarborough PM, Ribeiro A, Richardson R, Yuan H, Sonveaux P, et al. Catabolism of exogenous lactate reveals it as a legitimate metabolic substrate in breast cancer. PLoS ONE 2013;8:e75154.